Group items matching

in title, tags, annotations or url

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

Since the 1990s the congressional budget has included funds for the the Centers for Disease Control and Prevention (CDC) to reduce or prevent the complications of hemophilia and other congenital bleeding disorders. Since 1996 the CDC has funded the federal network of hemophilia treatment centers (HTCs) for the collection of data for the monitoring of health indicators of importance to persons with bleeding disorders. This data is used to measure rates of complications of bleeding disorders and monitor trends over time (including inhibitors and other issues of blood and treatment product safety); identify high risk populations for prevention programs; and identify issues that require research. The purpose of this FOA is to continue the surveillance for these conditions through the HTCs.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Vaccine and Treatment Evaluation Units (VTEUs) to implement clinical site protocols (clinical research, clinical trials) for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases as part of NIAID Infectious Diseases Clinical Research Consortium (IDCRC). The VTEUs coordinate with the Leadership Group (LG) for the IDCRC, a program which provides for overall administrative and scientific leadership for the clinical research and clinical trials conducted. This initiative seeks to fund additional VTEUs with a specific focus on enhancing capability and capacity of current research in controlled human infection models for malaria and influenza, and implementation of treatment and prevention trials in endemic areas for malaria and neglected tropical diseases. While the scientific focus will be on product evaluation for NIAID priorities for this FOA, including malaria/neglected tropical diseases, the VTEUs must also provide capacity to perform clinical research on sexually transmitted infections, respiratory infections, and enteric diseases in infected patients and healthy volunteers, in addition to providing surge capacity to address emerging infectious diseases.

The U.S. Environmental Protection Agency (EPA) is soliciting applications from eligible organizations to manage a cooperative agreement to help educate the medical community on how to recognize and treat pesticide-related health conditions. The long-term goal of the project is to achieve improved health for communities at risk for overexposure to pesticides through outreach, technical assistance and training to increase knowledge and awareness of environmental and occupational health risks. This is a national environmental and occupational health effort solicited by doctors, clinicians, and state health departments. With this award, EPA seeks to build on the progress of previous project titled "From the Fields to the Exam Room: Integrating the Recognition, Management and Prevention of Pesticide Poisonings into the Primary Care Setting." The publication "Recognition and Management of Pesticide Poisoning" was an earlier product of the initiative. EPA is seeking applications to (1) provide continuing education, training and technical assistance to relevant audiences; (2) update existing, and/or develop new materials and resource tools; (3) conduct outreach to existing and new audiences to use materials and tools; and (4) develop partnerships and a sustainable network of stakeholders. EPA expects to provide an estimated $500,000 annually, depending on the Agency's budget, for a total of up to $2,500,000 for five years (2017 through 2022).

Purpose of Program: The purpose of the RERC program is to improve the effectiveness of services authorized under the Rehabilitation Act by conducting advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or to remove environmental barriers. RERCs also demonstrate and evaluate such technologies, facilitate service delivery system changes, stimulate the production and distribution of new technologies and equipment in the private sector, and provide training opportunities. NIDILRR seeks to fund an RERC on Technologies to Promote Exercise and Health Among People with Disabilities. This RERC must investigate access to exercise by people with disabilities in both recreational and clinical settings and evaluate the impact of exercise on health outcomes of people with disabilities.

Announcement supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI. PIs should explain how their work will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines. TBI is defined as being caused by (1) a direct blow or impact to the head, (2) a penetrating head injury, or (3) an exposure to external forces such as blast waves that disrupt the function of the brain. Not all blows to the head or exposure to external forces result in a TBI. The severity of TBI may range from "mild," a brief change in mental status or consciousness, to "severe," an extended period of unconsciousness or confusion after the injury. Definitions of TBI severity can be found in Table 1 of the VA/DoD Clinical Practice Guideline for the Management of Concussion-Mild Traumatic Brain Injury. The FY17/18 PH/TBIRP CTRR-CRA supports clinical research but not clinical trials. Supported research can include observational research studies. The Clinical Research Award (CTRR-CRA) is intended to support clinical research focused on understanding the clinical sequelae and mechanisms of recovery associated with TBI and TBI rehabilitation interventions. The overarching goals of this award are to address TBI-related impairments and deficits including sensory, sensorimotor, and cognitive dysfunction to (1) develop and validate rehabilitation outcome measures; (2) define and evaluate mechanisms of injury progression or recovery associated with rehabilitation interventions; and (3) improve clinician-driven assessment strategies to guide return-to-duty decision making.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant. 

This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.

The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.

The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.

This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.

This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users are allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.

The purpose of the SCRI program is to address the critical needs of the specialty crop industry by awarding grants to support research and extension that address key challenges of national, regional, and multi-state importance in sustaining all components of food and agriculture, including conventional and organic food production systems.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease.  The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of this award are as follows.

The MBRP Clinical Trial Award mechanism is being offered for the first time in FY17.The objective of this Program Announcement is to explore innovative approaches to accelerate the translation of knowledge advances into new treatments for the Service members who sustain burn injuries. The results of the research funded through the FY17/18 MBRP Clinical Trial Award are expected to increase the body of knowledge and materiel products available to professionals and practitioners in health, medical science, and related fields. The research impact is expected to benefit both civilian and military communities.The FY17/18 MBRP Clinical Trial Award supports clinical research studies with the potential to have a major impact on the prevention, treatment, and mitigation of debilitating burn scars that are relevant to military personnel. The specific intent is to improve functional outcomes and/or assess clinical efficacy and safety of different treatment modalities (e.g., dressing topics, biologics, cell-based therapies, mechanical, photonics).

The FY17 HRRP TRA mechanism is being offered in this first year of the program to support preclinical translational research that will accelerate the movement of promising initiatives relevant to hearing restoration into clinical applications. The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the clinical introduction of healthcare products, technologies, or practice guidelines. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first-hand knowledge of patients and anecdotal data. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information between basic and clinical science.